Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).
Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, Ajaz Hussain S, Pedersen SD, Borowska L, Unseld A, Kloer IM, Kaplan LM; SYNCHRONIZE‐1 and ‐2 trial committees and investigators.
Wharton S, et al. Among authors: unseld a.
Obesity (Silver Spring). 2025 Jan;33(1):67-77. doi: 10.1002/oby.24184. Epub 2024 Nov 4.
Obesity (Silver Spring). 2025.
PMID: 39495965
Free PMC article.